Sage Rhino Capital LLC Reduces Position in Organon & Co. (NYSE:OGN)

Sage Rhino Capital LLC lessened its stake in shares of Organon & Co. (NYSE:OGN) by 5.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 15,070 shares of the company’s stock after selling 852 shares during the period. Sage Rhino Capital LLC’s holdings in Organon & Co. were worth $225,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Pacer Advisors Inc. boosted its holdings in shares of Organon & Co. by 94,482.1% in the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after acquiring an additional 11,140,388 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Organon & Co. by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company’s stock valued at $81,288,000 after acquiring an additional 82,220 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Organon & Co. by 35.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock valued at $63,570,000 after acquiring an additional 875,128 shares during the last quarter. Thompson Siegel & Walmsley LLC boosted its holdings in shares of Organon & Co. by 6.4% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 2,262,379 shares of the company’s stock valued at $43,279,000 after acquiring an additional 136,457 shares during the last quarter. Finally, Private Management Group Inc. boosted its holdings in shares of Organon & Co. by 11.9% in the 4th quarter. Private Management Group Inc. now owns 2,119,288 shares of the company’s stock valued at $31,620,000 after acquiring an additional 225,420 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Performance

OGN opened at $14.35 on Tuesday. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The firm has a fifty day moving average price of $15.43 and a 200 day moving average price of $17.05. The stock has a market cap of $3.70 billion, a P/E ratio of 4.31, a P/E/G ratio of 0.90 and a beta of 0.76. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Equities research analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 13th. Shareholders of record on Monday, February 24th will be given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 7.80%. The ex-dividend date of this dividend is Monday, February 24th. Organon & Co.’s dividend payout ratio is presently 33.63%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Morgan Stanley dropped their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, February 14th. TD Cowen raised shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Finally, Barclays dropped their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.